Current Clinical Trials

Bookmark and Share

Aug 26

T-Cell Leukemia Lymphoma Foundation

Current Clinical Trials

Posted by T-Cell Leukemia Lymphoma Foundation

Current Clinical Trials

CLINICAL TRIALS CURRENTLY AVAILABLE FOR PTCL & CTCL PATIENTS:

  • NCT01482962: Alisertib (MLN8237) or Investigator’s Choice in Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma
  • NCT01466881Alisertib in Treating Patients With Relapsed or Refractory Peripheral T-Cell Non-Hodgkin Lymphoma
  • NCT01796002Phase 3 Multi-center Randomized Study to Compare Efficacy and Safety of Romidepsin CHOP (Ro-CHOP) Versus CHOP in Patients With Previously Untreated Peripheral T-Cell Lymphoma
  • NCT01611142: Study of KW-0761 (Mogamulizumab) in Subjects with Previously Treated Peripheral T-Cell Lymphoma
  • NCT01590732Phase I Study of Romidepsin Plus ICE for Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma
  • NCT01336920Carfilzomib in Treating Patients With Relapsed or Refractory T-Cell Lymphoma
  • NCT01777152: ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas
  • NCT01352520SGN-35 in CD30-positive Lymphoproliferative Disorders (ALCL), Mycosis Fungoides (MF), and Extensive Lymphomatoid Papulosis (LyP)
  • NCT01738594Dose-Escalation Trial of Carfilzomib With and Without Romidepsin in Cutaneous T-Cell Lymphoma
  • NCT01637090Everolimus in Treating Cutaneous T-Cell Lymphoma
  • NCT01578499A Randomized, Open-Label, Phase 3 Trial of Brentuximab Vedotin (SGN-35) Versus Physician’s Choice (Methotrexate or Bexarotene) in Patients With CD30-Positive Cutaneous T-Cell Lymphoma
  • NCT01839097: Phase I Dose Finding Study of Belinostat Plus CHOP for Treatment of Patients with PTCL
  • NCT01728805Study of KW-0761 Versus Vorinostat in Relapsed/Refractory CTCL
  • NCT01626664KW-0761 or Investigator’s Choice in Subjects With Previously Treated Adult T-cell Leukemia-Lymphoma (ATL)
  • NCT00047060SCT Therapy with Campath-1H for Treating Advanced Mycosis Fungoides (MF) and Sezary Syndrome (SS)
  • NCT01805037:  Phase I/II Study of Brentuximab Vedotin + Rituximab as Frontline Therapy for Patients with CD30+ and/or EBV+ Lymphomas
  • NCT01660451Open-label, Uncontrolled Phase II Trial of Intravenous P13K Inhibitor BAY80-6946 in Patients with Relapsed, Indolent or Aggressive Non-Hodgkin’s Lymphomas
  • NCT01567709Alisertib in Combination with Vorinostat in Treating Patients with Relapsed or Recurrent Hodgkin Lymphoma, B-Cell Non-Hodgkin Lymphoma or Peripheral T-Cell Lymphoma
  • NCT01742793An Open Label, International, Multi-centre, Phase I/IIa Study of Lenalidomide (Revlimid) and Romidepsin (Istodax) for Relapsed/Refractory Hodgkin Lymphoma, Mature T-Cell Lymphoma and Multiple Myeloma
  • NCT01431209Ruxolitinib Phosphate (Oral JAK Inhibitor INCB18424) in Treating Patients with Relapsed or Refractory Diffuse Large B-Cell or Peripheral T-Cell Non-Hodgkin Lymphoma
  • NCT01678443Monoclonal Antibody Therapy Before Stem Cell Transplant in Treating Patients with Relapsed or Refractory Lymphoid Malignancies
  • NCT01261247Panobinostat in Treating Patients with Relapsed or Refractory Non-Hodgkin Lymphoma
  • NCT01703949Brentuximab Vedotin in Treating Patients with Relapsed or Refractory CD30+ Lymphoma

    blog08.26.14.jpg